Evidence map›Paper›PMID 27125378›Full record

ArticleInternational journal of clinical pharmacy2016

Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.

Takafumi Nakano, Yoshihiko Nakamura, Tohru Takata, Keiichi Irie, Kazunori Sano, Osamu Imakyure, Kenichi Mishima, Koujiro Futagami

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Takafumi NakanoDepartment of Pharmacy, Fukuoka University Hospital, Nanakuma 7-45-1, Jyonan-Ku, Fukuoka, 814-0180, Japan. naka0625@fukuoka-u.ac.jp.
Yoshihiko NakamuraDepartment of Emergency and Critical Care Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Tohru TakataDepartment of Oncology, Hematology, and Infectious Diseases, Fukuoka University, Fukuoka, Japan.
Keiichi IrieDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
Kazunori SanoDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
Osamu ImakyureDepartment of Pharmacy, Fukuoka University Hospital, Nanakuma 7-45-1, Jyonan-Ku, Fukuoka, 814-0180, Japan.
Kenichi MishimaDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
Koujiro FutagamiDepartment of Pharmacy, Fukuoka University Hospital, Nanakuma 7-45-1, Jyonan-Ku, Fukuoka, 814-0180, Japan.
Fukuoka University Hospital · JPFukuoka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Target trough concentrations are recommended for teicoplanin (TEIC) to minimize its adverse effects and to maximize efficacy in sepsis caused by grampositive cocci, including methicillin-resistant Staphylococcus aureus infection. However, optimal doses to attain proper trough values in patients with sepsis have not yet been well established for TEIC. Objective This study investigated whether the systemic inflammatory response syndrome (SIRS) score could predict the pharmacokinetics of TEIC in patients with sepsis. Setting This study was conducted at Fukuoka University Hospital in Japan. Methods We retrospectively reviewed the records of patients using TEIC between April 2012 and March 2015. SIRS positive was defined as infection with a SIRS score ≥2. Estimates of pharmacokinetic parameters were calculated using a Bayesian method. Creatinine clearance rates were estimated by the Cockcroft-Gault formula (eCcr). Main outcome measure Change of TEIC loading dose requirement for incremental increases of SIRS score. Results In total, 133 patients were enrolled: 50 non-SIRS patients and 83 patients with SIRS. The TEIC plasma trough concentration was significantly lower in SIRS than non-SIRS patients (15.7 ± 7.1 vs. 20.1 ± 8.6 μg/mL; P < 0.01), although there was no significant difference in the loading dose administered. Moreover, SIRS scores were increasingly predictive of eCcr and TEIC clearance in a stepwise manner. To achieve the target trough concentration (15-30 μg/mL), the optimal doses required in non-SIRS versus SIRS patients were 12-24 versus 18-30 mg/kg/day, respectively, during the first 48 h. Conclusions These findings suggest that the pharmacokinetics of TEIC are altered in SIRS patients, who required higher doses than non-SIRS patients to achieve the target trough concentration. We suggest that the SIRS score can become a new modality to determine the initial TEIC loading dose.

Indexed as

Drug Administration ScheduleAgedBayes TheoremCase-Control StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesSepsisSystemic Inflammatory Response SyndromeTeicoplaninTeicoplaninInflammatory responsePharmacokineticsSevere sepsisSystemic inflammatory response syndromeTeicoplanin

Identifiers

PMID27125378
OpenAlexW2343974728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.